Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised Double-Blind Clinical Efficacy and Safety Comparison of Tiotropium/Salmeterol 7.5/25 Mcg Inhalation Powder in the Morning Via Tiotropium/Salmeterol HandiHaler Tiotropium 18 Mcg Inhalation Powder in the Morning Via Spiriva HandiHaler Salmeterol 50 Mcg MDPI [metered dose powder inhaler] in the Morning and Evening and the Free Combination Tiotropium 18 Mcg Inhalation Powder in the Morning Via Spiriva HandiHaler Plus Salmeterol 50 Mcg MDPI in the Morning and Evening Following Chronic Administration (6-Week Treatment Periods) in Patients With COPD [Chronic Obstructive Pulmonary Disease].

Next Previous
Search
Trial Profile

A Randomised Double-Blind Clinical Efficacy and Safety Comparison of Tiotropium/Salmeterol 7.5/25 Mcg Inhalation Powder in the Morning Via Tiotropium/Salmeterol HandiHaler Tiotropium 18 Mcg Inhalation Powder in the Morning Via Spiriva HandiHaler Salmeterol 50 Mcg MDPI [metered dose powder inhaler] in the Morning and Evening and the Free Combination Tiotropium 18 Mcg Inhalation Powder in the Morning Via Spiriva HandiHaler Plus Salmeterol 50 Mcg MDPI in the Morning and Evening Following Chronic Administration (6-Week Treatment Periods) in Patients With COPD [Chronic Obstructive Pulmonary Disease].

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiotropium bromide (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 28 Apr 2012 Actual end date changed from 1 Jul 2009 to 26 Aug 2009 as reported by European Clinical Trials Database.
    • 28 Apr 2012 Planned number of patients changed from 140 to 160 as reported by European Clinical Trials Database.
    • 28 Apr 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2007-005135-28).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top